Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Third Harmonic Bio is a biopharmaceutical company developing oral, highly selective KIT inhibitors to treat mast cell-driven inflammatory diseases such as chronic spontaneous urticaria. Its lead candidate, THB335, aims to provide a convenient, targeted therapy with potential applications across skin, respiratory, and gastrointestinal conditions. The company focuses on innovative drug development, leveraging proprietary technology and strategic licensing to address unmet medical needs in allergy and inflammation.
This description was generated via AI from an annual report. Updated about 1 year ago.